Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., . . . Usmani, S. Z. (2021). Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial. The lancet. Oncology, 22(11), . https://doi.org/10.1016/S1470-2045(21)00466-6
Chicago-Zitierstil (17. Ausg.)Facon, Thierry, et al. "Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Newly Diagnosed Multiple Myeloma (MAIA): Overall Survival Results from a Randomised, Open-label, Phase 3 Trial." The Lancet. Oncology 22, no. 11 (2021). https://doi.org/10.1016/S1470-2045(21)00466-6.
MLA-Zitierstil (9. Ausg.)Facon, Thierry, et al. "Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Newly Diagnosed Multiple Myeloma (MAIA): Overall Survival Results from a Randomised, Open-label, Phase 3 Trial." The Lancet. Oncology, vol. 22, no. 11, 2021, https://doi.org/10.1016/S1470-2045(21)00466-6.